Table of Contents
Helmholtz Group Oncolytic Adenoviruses, DKFZ (German Cancer Research Center)
Im Neuenheimer Feld 242
+49 (0)6221 42-4451
Carrier Cell-Mediated Delivery
Pancreatic cancer has one of the worst prognoses of malignant tumor types. At the point of diagnosis the tumor has often far progressed in malignancy and metastasis formation. Therefore, applied therapies have only palliative function. Oncolytic adenoviruses have been shown to efficiently lyse tumor cells in several cancer types and will be utilized in this project for pancreatic tumor cell lysis. The generated adenoviruses will furthermore be tested to eliminate the tumor stem cell subpopulation, as these cells are known to be resistant to common chemo-and radiotherapies, remain in the tissue after treatment, and have the potency to cause reoccurrence of the tumor. However, adenoviral infections are very common and systemic application of therapeutic adenovirus would lead to clearance of virus by the immune system. This problem we will circumvented by using mesenchymal stem cells (MSCs) as carrier cells, which have been shown to specifically home to the tumor tissue.
The overall goal of this PhD thesis is to develop oncolytic adenoviruses for pancreatic cancer treatment, especially considering pancreatic tumor stem cell lysis and using MSCs as carriers.